STOCK TITAN
  1. Home
  2. News
  3. FNA

Paragon 28 Inc - FNA STOCK NEWS

Welcome to our dedicated news page for Paragon 28 (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Paragon 28's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Paragon 28's position in the market.

News
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) has announced the launch of the Grappler® Knotless Anchor System and Bridgeline™ Tape, aimed at enhancing the company's position in the fast-growing foot and ankle specific soft tissue market in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.85%
Tags
none
-
News
Paragon 28 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Paragon 28, Inc. (FNA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
conferences
-
News
Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) Launches BEAST™ Cortical Fibers, a biologic product designed to aid cellular attachment, differentiation, and bone formation. The press release highlights the product's porous structure, flexibility, and ability to support efficient bone remodeling. The company's biologics product offering is further strengthened with this addition, providing innovative solutions for reconstruction and trauma in foot and ankle surgical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
News
Paragon 28 Launches JAWS™ Great White Staple System Further Expanding its Nitinol Staple Offering
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announces the launch of its JAWS™ Great White Staple System, offering increased strength and stability for osteotomy or fusion sites. The staples feature an ultra-low-profile bridge with enhanced surface area to minimize soft tissue irritation, providing 400 times the fatigue life of a competitive nitinol staple. The shoulders of the staple work in conjunction with the inserter, allowing full seating prior to compression activation, limiting the need to tamp. Paragon 28’s CEO, Albert DaCosta, expressed excitement about expanding their staple offering to address midfoot and hindfoot reconstruction complexities, enhancing market position in these segments. The addition of the JAWS™ Great White Staple System complements Paragon 28’s hindfoot solutions product offering, providing innovative ankle solutions for trauma, arthritis, and limb salvage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
none
-
News
Paragon 28 Adds Second Mobile Medical Education Lab Significantly Expanding Upon Wildly Successful Foot and Ankle Surgeon Training Program
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announces the addition of a second trailer to its nationwide mobile lab training program, providing a state-of-the-art, 5 station, cadaveric training facility to accommodate up to 25 surgeons. The mobile lab will host over 70 training sessions in approximately 65 US cities during quarter four of 2023, following a successful kick-off in July 2022. CEO Albert DaCosta emphasizes the program's effectiveness in supporting the company's growing product portfolio and surgeon customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
none
-
News
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) secures $150 million credit facility from Ares Capital Corporation, replacing existing $90 million senior credit facility. The non-dilutive facility includes $100 million in term loans and a $50 million revolving credit facility, reinforcing the company's pathway to cash flow break-even.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) reported Q3 2023 financial results with $52.8 million net revenue, 14.7% growth, and reaffirmed 2023 net revenue guidance of $214-218 million, representing 19-20% growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
earnings
-
News
Paragon 28 to Present at Upcoming Investor Conferences
Rhea-AI Summary
Paragon 28, Inc. (NYSE: FNA) announced that its Chairman and CEO, Albert DaCosta, and CFO, Steve Deitsch, will be presenting at two upcoming investor conferences. They will participate in the Stephens Annual Investment Conference on November 15, 2023, and the 35th Annual Piper Sandler Healthcare Conference on November 28, 2023. The fireside chats will be available for live and archived webcasts on the company's website at ir.paragon28.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
conferences
-
News
Paragon 28 To Report Third Quarter Financial Results on November 7, 2023
Rhea-AI Summary
Paragon 28, Inc. to report financial results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences earnings
News
Paragon 28®, Inc. Receives FDA Approval for IDE Feasibility Study of Its SMART Total Talus™ System for use in Conjunction with the APEX 3D™ Total Ankle Replacement System
Rhea-AI Summary
Paragon 28 received FDA approval for a feasibility study on the SMART Total Talus System, which aims to improve patient outcomes and expand options for ankle replacement candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
fda approval
Stock FNA logo
Paragon 28 Inc

NYSE:FNA

FNA Rankings

#2666 Ranked by Market Cap
#4883 Ranked by Stock Gains
N/A Ranked by Dividends

FNA Stock Data

849.79M
39.20M
40.06%
49.64%
2.93%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Englewood

About FNA

paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen